secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001404644-25-000029
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene raises BBA director nomination threshold to 14.9%, exchanges shares for prefunded warrants
--------------------------------------------------------------------------------

- BBA director nomination threshold raised from 12.5% to 14.9% of voting common stock via amendment to July 2023 letter agreement.
- Exchange agreement: 667,500 common shares swapped for prefunded warrants to buy 667,563 shares at $0.001 exercise price.
- Post-exchange: 14,262,066 common shares outstanding; 6,792,559 prefunded warrants outstanding.
- Prefunded warrants have 4.99% beneficial ownership limitation, adjustable up to 19.99% with 61 days' notice.
- Exchange expected to close April 14, 2025, exempt from registration under Section 3(a)(9).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000029/0001404644-25-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000029/ngne-20250414.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer